Recent News

• 06.09.2025 - IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
• 05.28.2025 - IceCure Medical Reports First Quarter 2025 Financial Results
• 05.21.2025 - IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
• 05.06.2025 - IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
• 04.30.2025 - IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
• 04.28.2025 - IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
• 04.22.2025 - IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
• 03.31.2025 - IceCure to Exhibit and Join the Hands-on Cryoablation Sessions at the European Conference on Interventional Oncology (ECIO) 2025
• 03.27.2025 - IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Recent Filings

• 05.28.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.14.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 04.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - EX-99.1 EX-99.1
• 04.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.27.2025 - EX-99.1 EX-99.1